Ovation Science AAQS
The The AAQS of Ovation Science (OVAT.CN) as of Oct 31, 2026 is 3. In the previous year, The AAQS was 3.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
3
YoY
0.00%
Last updated:
Ovation Science has a current AAQS of 3.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Ovation Science in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock Ovation Science in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The Ovation Science AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2018
3.00 CAD
Jan 1, 2019
3.00 CAD
Jan 1, 2020
3.00 CAD
Jan 1, 2021
3.00 CAD
Jan 1, 2022
3.00 CAD
Jan 1, 2023
3.00 CAD
Jan 1, 2024
3.00 CAD
Jan 1, 2025
3.00 CAD
| YEAR | AAQS | YoY |
|---|---|---|
| 3 | 0.00% | |
| 3 | 0.00% | |
| 3 | 0.00% | |
| 3 | 0.00% | |
| 3 | 0.00% | |
| 3 | 0.00% | |
| 3 | 0.00% | |
| 3 | 0.00% | |
| 3 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Ovation Science Stock analysis
What does Ovation Science do? Ovation Science, Inc. generates revenue through the development and sale of topical and transdermal skin products utilizing its patented Invisicare delivery technology. The company offers products under the Ovation brand, ARLO CBD Beauty, and InVibe MD, featuring formulations with hemp seed oil, CBD, THC, and cannabinoid derivatives. These products are distributed through direct sales and licensing agreements, targeting consumers seeking science-based skincare and wellness solutions. The firm leverages its Invisicare technology to create creams and lotions that deliver cannabinoids and hemp seed oil effectively for topical and transdermal use.
The company's product portfolio includes ARLO CBD Beauty for skincare and InVibe MD for wellness, both powered by the Invisicare delivery system. Ovation Science licenses its technology and products to third parties while also selling directly under its own brands. The primary market segments are consumers interested in cannabinoid-based skincare and wellness products, with a focus on the efficacy and science-backed nature of their formulations. All products are manufactured and distributed under the company's brand labels, emphasizing the patented delivery system as a key differentiator.
Ovation Science, Inc. monetizes its patented Invisicare technology by developing and distributing products containing cannabinoids, hemp seed oil, and synthetic cannabis derivatives. The company's revenue streams come from both direct sales of Ovation-branded products and licensing agreements for its technology and formulations. The firm's focus on topical and transdermal delivery ensures that its products are positioned within the growing market for cannabinoid-infused skincare and wellness solutions, targeting customers who prioritize the science and technology behind their skincare products. Ovation Science is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Ovation Science stock
The AAQS of Ovation Science is 3 in 2025.
On Eulerpool you can find the complete historical development of The AAQS Ovation Science since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Ovation Science
All Key Metrics — Ovation Science
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth